Bristol Myers Squibb’s Zeposia (ozanimod) Receives CHMP’s Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis Published: 15 Oct, 2021 | Tags: Bristol Myers Squibb, Zeposia, ozanimod, […]readmore
Tags : Aurigene
Shots: Aurigene to fund and conduct P-IIb/III study assessing CA-170 + chemoradiation in ~240 patients with nsq. NSCLC and get exclusive rights to develop and commercialize CA-170 in Asia in […]readmore
Shots: Aurigene to receive 10M upfront while Exelixis get an option to license three developed programs from Aurigene. Additionally, Exelixis and Aurgene is developing three discovery programs, for which Exelixis […]readmore